PMID- 37646973
OWN - NLM
STAT- Publisher
LR  - 20231023
IS  - 1749-0774 (Electronic)
IS  - 0914-7470 (Print)
IS  - 0914-7470 (Linking)
VI  - 36
IP  - 6
DP  - 2023 Nov
TI  - The role of mitochondrial/metabolic axis in development of tamoxifen resistance 
      in breast cancer.
PG  - 1877-1886
LID - 10.1007/s13577-023-00977-5 [doi]
AB  - Only a few investigations, to our knowledge, have examined the bioenergetics of 
      Tamoxifen (TMX) resistant individuals and reported altered mitochondrial activity 
      and metabolic profile. The primary cause of TMX resistance is firmly suggested to 
      be metabolic changes. Metabolic variations and hypoxia have also been linked in a 
      bidirectional manner. Increased hypoxic levels correlate with early recurrence 
      and proliferation and have a negative therapeutic impact on breast cancer (BC) 
      patients. Hypoxia, carcinogenesis, and patient death are all correlated, 
      resulting in more aggressive traits, a higher chance of metastasis, and TMX 
      resistance. Consequently, we sought to investigate the possible role of the 
      metabolic/hypoxial axis Long non-coding RNA (LncRNA) Taurine up-regulated 1 
      (TUG-1), Micro-RNA 186-5p (miR-186), Sirtuin-3 (SIRT3), Peroxisome Proliferator 
      Activator Receptor alpha (PPAR-alpha), and Hypoxia-Inducible Factor-1 (HIF-1) in the 
      development of TMX resistance in BC patients and to correlate this axis with 
      tumor progression. Interestingly, this will be the first time to explore 
      epigenetic regulation of this axis in BC.
CI  - (c) 2023. The Author(s).
FAU - Azzam, Hany N
AU  - Azzam HN
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Heliopolis 
      University, Cairo, Egypt.
FAU - El-Derany, Marwa O
AU  - El-Derany MO
AD  - Department of Biochemistry, Faculty of Pharmacy, Ain Shams University, Cairo, 
      Egypt.
FAU - Wahdan, Sara A
AU  - Wahdan SA
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams 
      University, Cairo, Egypt.
FAU - Faheim, Reham M
AU  - Faheim RM
AD  - Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain 
      Shams University, Cairo, Egypt.
FAU - Helal, Gouda K
AU  - Helal GK
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Heliopolis 
      University, Cairo, Egypt.
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar 
      University, Cairo, Egypt.
FAU - El-Demerdash, Ebtehal
AU  - El-Demerdash E
AUID- ORCID: 0000-0003-2951-4892
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams 
      University, Cairo, Egypt. ebtehal_dm@yahoo.com.
AD  - Preclinical & Translational Research Center, Faculty of Pharmacy, Ain Shams 
      University, Cairo, Egypt. ebtehal_dm@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230830
PL  - Japan
TA  - Hum Cell
JT  - Human cell
JID - 8912329
SB  - IM
PMC - PMC10587280
OTO - NOTNLM
OT  - Breast cancer
OT  - Hypoxia
OT  - Metabolic alterations
OT  - Mitochondrial activity
OT  - Tamoxifen
COIS- The authors have no conflicts of interest to declare.
EDAT- 2023/08/30 12:43
MHDA- 2023/08/30 12:43
PMCR- 2023/08/30
CRDT- 2023/08/30 11:11
PHST- 2023/03/16 00:00 [received]
PHST- 2023/08/20 00:00 [accepted]
PHST- 2023/08/30 12:43 [pubmed]
PHST- 2023/08/30 12:43 [medline]
PHST- 2023/08/30 11:11 [entrez]
PHST- 2023/08/30 00:00 [pmc-release]
AID - 10.1007/s13577-023-00977-5 [pii]
AID - 977 [pii]
AID - 10.1007/s13577-023-00977-5 [doi]
PST - ppublish
SO  - Hum Cell. 2023 Nov;36(6):1877-1886. doi: 10.1007/s13577-023-00977-5. Epub 2023 
      Aug 30.